Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer

Related Experiment Video

Updated: Dec 10, 2025

Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

4.9K

B J Rimel1, Lauren Dockery2, Leslie M Randall3

  • 1Cedars-Sinai Medical Center, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Los Angeles, CA 90048, USA.

Future Oncology (London, England)
|September 4, 2020
PubMed

Insights

Niraparib, a poly(ADP-ribose) polymerase inhibitor, is effective for ovarian cancer maintenance therapy. This review covers its mechanism, efficacy, and combinations, highlighting its impact on treating this lethal gynecologic malignancy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Ovarian cancer is the most lethal gynecologic malignancy.
  • Homologous recombination deficiency (HRD) is a key feature of ovarian cancer, creating a DNA repair defect.
  • This DNA repair defect creates a dependency on functional poly(ADP-ribose) polymerase (PARP).

Purpose of the Study:

  • To review the mechanism of action of niraparib.
  • To summarize the efficacy of niraparib as a single agent and in novel combinations for ovarian cancer.
  • To discuss the toxicities associated with niraparib treatment.

Main Methods:

  • Literature review of preclinical and clinical studies on niraparib in ovarian cancer.
  • Analysis of data on niraparib's pharmacologic properties and clinical trial outcomes.
  • Synthesis of information on niraparib's role in maintenance therapy and combination treatments.

Main Results:

  • Niraparib is an orally available poly(ADP-ribose) polymerase inhibitor approved for ovarian cancer maintenance therapy.
  • It has demonstrated efficacy in treating ovarian cancer, altering the treatment landscape.
  • Ongoing evaluation of overall survival data is pending.

Conclusions:

  • Niraparib represents a significant advancement in ovarian cancer treatment, particularly for patients with homologous recombination deficiency.
  • Understanding its mechanism, efficacy, and toxicity is crucial for optimizing its use.
  • Further research into novel combinations may further enhance patient outcomes.
Keywords:
PARP inhibitorshomologous recombination deficiencyniraparibovarian cancer

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.1K
Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

12.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K